Tingyu Ban et al. found that flavonoids could regulate cancer pathways by controlling targets such as PTGS2, HSP90AA1, PGR, and PRKACA, thus treating HF caused by non-alcoholic fatty liver disease (32). Here, PRKACA is linked to metabolic dysfunction-associated steatotic liver disease.